Biogen: Wedbush keeps neutral rating. PT down to $183 from $188.
Comerica: Wedbush raises price target to $94 from $89, maintains outperform rating.
Compass: Morgan Stanley downgrades to equalweight from overweight and lowers price target to $5 from $7.
GSK Plc: Spin-Off Research downgr…
© MarketScreener.com 2022
next post